Recently, the Ministry of Education announced the registration and approval results of undergraduate majors in colleges and universities for 2024, and Shanghai Normal University was approved to add a new undergraduate major in bio-pharmaceuticals.
The bio-pharmaceutical major will start enrollment in the autumn of 2025, relying on the high-quality resources of the School of Life Sciences, focusing on cutting-edge technologies in bio-medicine, and cultivating interdisciplinary talents in the bio-pharmaceutical field with innovative abilities and international perspectives.
Bio-pharmaceuticals is one of the most promising strategic emerging industries in the 21stcentury. The SHNU has established a three-in-one curriculum system of theory+technology+practice, creating professional characteristic courses such as natural product drugs, genetic engineering drugs, antibody drugs, gene editing, etc., and integrating cutting-edge directions such as artificial intelligence assisted drug design, focusing on solving technical problems in the field of bio-medicine. The school relies on research platforms such as the Biomedical Industry Education Integration Innovation Center, and has established deep cooperation with more than 20 well-known enterprises and research institutions such as Fosun Pharma and Shanghai Pharmaceutical Group to jointly build an integrated training system of curriculum training research and development. In addition, the major construction will also involve advanced teaching facilities such as GMP simulation workshops and virtual simulation laboratories for bioreactors.
The approval of this new major marks an important step for the SHNU in serving the strategic needs of the country and Shanghai, deepening the construction of new engineering disciplines, and promoting talent cultivation in the field of bio-medicine.
